HER-096 clinical development risk
The lead asset must continue to show safety, tolerability, and efficacy in humans.
- Scope
- Phase 2 and beyond
- Materiality
- high
Herantis Pharma Oyj
Herantis Pharma is a Helsinki-based clinical-stage biotechnology company focused on developing disease-modifying treatments for Parkinson's disease. Its core program, HER-096, is a small peptide designed for subcutaneous administration and intended to reach the brain through the blood-brain barrier.
13
2.92
2.88
| % | |
|---|---|
| HER-096 clinical program | 85% Development of the lead peptide candidate HER-096 for Parkinson's disease. |
| Research collaborations and grants | 15% Non-dilutive research funding and partnered development support. |
Herantis does not sell a commercial product to mass-market end customers; its primary counterparties are clinical trial...
- Clinical trial participantsprimary
Healthy volunteers and Parkinson's patients enrolled to test safety, tolerability, PK, and biomarkers.
- Research funderssecondary
Public and private grant providers that finance development work and reduce dilution.
- Future healthcare providersemerging
Neurologists, hospitals, and health systems that would prescribe or administer HER-096 if approved.
- Potential licensing partnersemerging
Pharma or biotech partners that may support later-stage development or commercialization.
Herantis is headquartered in Helsinki, Finland, and is listed on Nasdaq First North Helsinki...
- •Headquartered in Helsinki, Finland
- •Listed on Nasdaq First North Helsinki
- •Clinical development is international by nature
- •European grant funding supports research activity
- •Future market access would likely be multi-country
Herantis' strategy centers on advancing HER-096 through clinical proof-of-concept, using biomarker data to strengthen...
01
Progress HER-096 into phase 2 proof-of-conceptshort-term
Later-stage human data is the key value inflection for a clinical-stage biotech.
02
Strengthen the clinical and biomarker packageshort-term
Robust biomarker evidence can improve differentiation and de-risk development.
03
Secure funding for developmentshort-term
Clinical trials are capital intensive and require continuous financing.
04
Preserve partnering optionalitymedium-term
A stronger data package can improve future licensing or collaboration terms.
Herantis is exposed to the core risks of clinical-stage drug development: trial failure, regulatory setbacks, and...
Financing risk
Clinical development requires recurring capital and the company may need additional funding.
- Scope
- Operating runway and trial execution
- Materiality
- high
Regulatory and approval risk
Drug candidates can be delayed or rejected by regulators even after promising early data.
- Scope
- Clinical and commercialization path
- Materiality
- high
Intellectual property risk
A small biotech's value depends heavily on protecting its lead asset and know-how.
- Scope
- Patents and proprietary data
- Materiality
- high
Third-party dependency risk
Trials, lab work, and manufacturing rely on external partners and vendors.
- Scope
- CROs, labs, clinical sites, manufacturing
- Materiality
- medium
Research and development expense recognition
Material for operating result and comparability across periods
Grant accounting
Affects other operating income and funding visibility
Share-based payment accounting
Can materially affect operating expenses
Potential future licensing revenue
Could affect timing and volatility of reported revenue
: 11/08/2026